Stephanie Henriquez, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 12907 W Greenway Rd, El Mirage, AZ 85335 Phone: 623-876-7404 |
Ms. Alicia Rightnour, L.P.N Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 12501 W Myer Ln, El Mirage, AZ 85335 Phone: 623-691-5615 |
Ms. Kathleen L Eppich, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 11800 W Thompson Ranch Rd, El Mirage, AZ 85335 Phone: 623-523-8440 Fax: 623-523-8411 |
Victoria Lynne Bayne, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 12701 N Main St, El Mirage, AZ 85335 Phone: 623-523-8990 Fax: 623-523-8961 |
Ms. Karen Lynn Hudson, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 12016 W Bloomfield Rd, El Mirage, AZ 85335 Phone: 623-974-4427 |
Lisa M Case, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 12426 W Surrey Ave, El Mirage, AZ 85335 Phone: 712-212-1327 |
Ms. Mary Beth Paul, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 12725 W Boca Raton Rd, El Mirage, AZ 85335 Phone: 623-760-3153 |
Mrs. Luella Pauline Martin, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 11800 W Thompson Ranch Rd, El Mirage, AZ 85335 Phone: 623-523-8404 Fax: 623-523-8411 |
Mrs. Jennifer Lynne Butler, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 12807 W Ash St, El Mirage, AZ 85335 Phone: 623-933-0257 |
News Archive
Novartis today announced data from the largest clinical trial of myelofibrosis patients treated with Jakavi (ruxolitinib), supporting the safety profile and efficacy benefit as measured in primary and secondary endpoints respectively.
An international study of integrated HHV-6 has discovered that a small number of human ancestors, one from about 24,000 years ago, have been responsible for transmitting ancient strains of the virus to individuals today - affecting about a million people in the UK alone.
Celldex Therapeutics, Inc. today announced that the first patient has been treated in a randomized Phase 2b study of the Company's CDX-011 (glembatumumab vedotin) antibody drug conjugate in glycoprotein NMB (GPNMB) expressing advanced, refractory breast cancer patients. CDX-011 targets the protein GPNMB, which is over expressed in a variety of cancers including breast cancer, melanoma, and brain tumors.
Electronic health record systems significantly improve outcomes for patients who undergo surgeries on weekends, according to a Loyola Medicine study published in JAMA Surgery.
› Verified 7 days ago